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Abstract
Corticotropin-releasing hormone, or factor, (CRH or CRF) exerts important biological effects in multiple peripheral tissues via
paracrine/autocrine actions. The aim of our study was to assess the effects of endogenous CRH in the biology of mouse and
human skin fibroblasts, the primary cell type involved in wound healing. We show expression of CRH and its receptors in
primary fibroblasts, and we demonstrate the functionality of fibroblast CRH receptors by induction of cAMP. Fibroblasts
genetically deficient in Crh (Crh2/2) had higher proliferation and migration rates and compromised production of IL-6 and
TGF-b1 compared to the wildtype (Crh+/+) cells. Human primary cultures of foreskin fibroblasts exposed to the CRF1
antagonist antalarmin recapitulated the findings in the Crh2/2 cells, exhibiting altered proliferative and migratory behavior
and suppressed production of IL-6. In conclusion, our findings show an important role of fibroblast-expressed CRH in the
proliferation, migration, and cytokine production of these cells, processes associated with the skin response to injury. Our
data suggest that the immunomodulatory effects of CRH may include an important, albeit not explored yet, role in
epidermal tissue remodeling and regeneration and maintenance of tissue homeostasis.
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Introduction
Wound healing is a highly coordinated, dynamic, and interactive
process aiming to repair the injury and restore the functional
integrity of the wounded tissue. Following skin injury, different cell
types interact to initiate a sequence of events that includes
coagulation, inflammation, and formation of granulation tissue,
re-epithelialization and finally remodeling [1]. Dermal fibroblasts
are critical cells in this process through their proliferation, ordered
migration into the provisional matrix, production of extracellular
matrix and differentiation into myofibroblasts [2]. The above
together with the fibroblast-mediated effects on keratinocyte
proliferation, differentiation, and migration place these cells in a
critical position for re-epithelialization and preservation of epider-
mal homeostasis after tissue injury [3].
Interleukin (IL)-6 and other proinflammatory cytokines and growth
factors, produced locally in both human and murine skin cells and
resident immune cells, is a major regulator of the healing process. IL-6
is a pleiotropic cytokine involved in the growth and differentiation of
numerous cell types including those of dermal and epidermal origin
[4]. In the skin IL-6 is produced primarily by epidermal keratinocytes
and to a lesser degree by resident macrophages, Langerhans cells and
fibroblasts in the dermis [5]. IL-6 is readily detected in cutaneous
wounds [6], and in the supernatant of keratinocyte cultures subjected
to in vitro wounding [7]. High levels of IL-6 have been associated to a
number of skin pathologies, while mice genetically deficient in IL-6
(Il62/2) display significantly delayed wound healing compared to
wild-type animals [8].
A second major regulator of wound healing is the transforming
growth factor (TGF)-b1 a growth factor that regulates cell
proliferation, adhesion, migration and differentiation, and finally
extracellular matrix deposition [9]. TGF-b1 has been shown to act
as a mitogen and chemoattractant for fibroblasts and as inducer of
myofibroblast differentiation [10]. Treatment with exogenous
TGF-b1 has been shown to improve the healing process [11].
Corticotropin-Releasing Hormone or Factor (CRH or CRF), a
41-amino acid peptide and the major activator of the hypotha-
lamic–pituitary–adrenal axis (HPA), has potent immunomodula-
tory properties [12] [13]. In vitro studies have shown that CRH
modulates the secretion of the proinflammatory cytokines IL-1, IL-
2, and IL-6 [14] [15] [16]. The development of the Crh-deficient
(Crh2/2) mouse [17] has provided important information on the
role of endogenous CRH in the activation of the immune system
and the inflammatory response [18][19]. Crh2/2 mice exhibited
significantly diminished inflammatory response in two experimen-
tal models of localized inflammation, carrageenin [20] and
turpentine [21], while in preliminary studies we have found that
Crh2/2 mice have accelerated wound closure (unpublished data).
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peripheral tissues and organs including skin [22] where it has dual
activity, direct proinflammatory and indirect anti-inflammatory
[23] [24] [25]. In the human skin, CRF1 and particularly the
CRF1alpha isoform, is the major receptor subtype expressed in
both epidermal and dermal compartments, whereas CRF2 is
detected predominantly in dermal structures. In rodent skin, both
CRH receptors are expressed with CRF1 the predominant form in
the keratinocytes and CRF2 in the panniculus carnosus [22].
Human normal or cancer skin cell lines express the Crh transcript,
while in the mouse skin CRH has been suggested to derive from
nerve endings [22]. CRH inhibits the proliferation of normal
neonatal keratinocytes [22], whereas CRH-induced activation of
the pro- and anti-inflammatory cytokines IL-6 and IL-11 and
inhibition of IL-1b release from human keratinocytes was shown
[26]. Furthermore, it has been hypothesized that skin CRH
mediates the activation of the tissue response to local stressors,
including inflammation and injury [27] [28]. Immunoreactive
CRH has been identified in fibroblasts, monocytes, and endothe-
lium of inflamed tissues [29] but its specific effects in dermal
fibroblasts have not been studied.
Aim of the present work was to examine the presence of the
CRH system (ligand and receptors) in murine skin fibroblast and
evaluate its effect on several parameters of these cells. For this
purpose we have studied the expression of CRH and its receptors
in murine skin fibroblast, the effects of CRH on fibroblast
proliferation, apoptosis and migration and its specific effect on the
production of two major factors affecting wound healing that of
IL-6 and TGF-b1. For this purpose, we have used fibroblasts
isolated from the skin of wildtype (Crh+/+) and Crh deficient
(Crh2/2) mice as well as from normal human foreskin.
Results
Expression of CRH and functional CRF1 and CRF2
receptors in murine fibroblasts
Crh mRNA expression was evaluated in murine fibroblasts
isolated from newborn wildtype (Crh+/+) mice. A Crh transcript of
identical molecular size to that of brain Crh was found in
fibroblasts, as expected, while no similar band was detectable in
Crh2/2 fibroblasts (Fig. 1a). Furthermore, IR-CRH was
measurable in the culture media of Crh+/+ fibroblasts at
concentrations of 0.860.21 ng/mg of total protein. We also
assessed the expression of both Crf1 and Crf2 in fibroblasts isolated
from Crh+/+ mice. Both transcripts were detectable in more or less
similar levels (Fig. 1b, 1c). To characterize the CRH receptors
present in murine fibroblasts, we determined their binding
capacity as well as their ability to stimulate cAMP accumulation.
As shown in figure 1d treatment of membrane homogenates from
Crh+/+ fibroblasts with the CRF1- and CRF2-selective antagonists,
antalarmin and astressin 2B, respectively, decreased
125I-Tyr
0-
sauvagine binding suggesting the presence of both (CRF1 and
CRF2) proteins, in these cells. Interestingly, treatment with CRH
at the saturating concentration of 250 nM was unable to
significantly increase the already elevated basal cAMP levels in
these cells (Fig. 1e) suggesting that endogenous CRH had
saturated both receptors expressed in fibroblasts, and had,
maximally, stimulated the CRF receptor-mediated cAMP accu-
mulation. To confirm the role of endogenous CRH we assessed
the expression, binding capacity, and CRH-stimulated cAMP
accumulation of both types of CRH receptors in fibroblasts
isolated from Crh2/2 newborn mice. We found that both Crf1
and Crf2 transcripts and proteins (measured by RT-PCR and
FACS analysis), were present in the Crh2/2 mice at levels similar
to those of Crh+/+ fibroblasts. Treatment of Crh2/2 fibroblasts
with either antalarmin or astressin 2B reduced
125I-Tyr
0-sauvagine
binding confirming the presence of specific CRH binding sites
(Fig. 1d). Interestingly, in contrast to Crh+/+ fibroblasts, treatment
of Crh2/2 fibroblasts with CRH significantly increased cAMP
accumulation at levels reaching the basal or CRH-stimulated ones
in Crh+/+ fibroblasts confirming the role of endogenous CRH
(Fig. 1e).
Effect of endogenous CRH on the proliferation and
apoptosis of murine fibroblasts
To assess the biological significance of CRH in murine dermal
fibroblasts, we compared the proliferation rates of Crh2/2 and
Crh+/+ fibroblasts by performing MTT and thymidine incorpo-
ration methods. Both types of assays showed that basal
proliferation rate of Crh2/2 fibroblasts was much higher
compared to Crh+/+ fibroblasts suggesting that the endogenous
CRH exerts a suppressive effect on fibroblast proliferation (Fig. 2a).
To assess the possibility that the suppressive effect of CRH on
fibroblast proliferation also involve parallel effects on their apoptosis
we also examined the effect of endogenous CRH on apoptosis.
Thus, we examined apoptosis in Crh+/+ and Crh2/2 fibroblasts
subjected to serum free starvation. Measurement of Annexin V
thirty hrs following serum starvation showed no difference in the
apoptosis levels between the two genotypes suggesting that
endogenous CRH has no effect on apoptosis (Fig. 2b).
Effect of endogenous CRH on murine fibroblast
migration
To determine a possible effect of CRH on the migratory
capacity of fibroblasts in vitro we have used a scratch-wounding
assay. Two types of experiments were performed in order to
minimize cell proliferation for the migration assay to be valid: In
the first set, the cells were pre-incubated for 2 hr with mitomycin
in serum supplemented conditions before the scratch assay was
performed while in the second set the cells were cultured in serum
free conditions. As shown (Fig. 3a and b) within 24 hrs from the
induction of the wound, the number of Crh2/2 cells migrated
into the wounded area was significantly higher compared to that of
Crh+/+ cells suggesting that the endogenous CRH exerts a
suppressive effect on the migration of fibroblasts.
Effect of endogenous CRH on IL-6 and TGF-b1
production by murine fibroblasts
Basal IL-6 and TGF-b1 secretion was significantly lower at all
time points studied, in the media of Crh2/2 fibroblasts (Fig. 4a
and 4b, respectively) suggesting that endogenous CRH exerts a
pro-inflammatory effect on fibroblast a phenomenon described
already for several types of immune cells.
Effects of endogenous CRH on human fibroblasts
Human primary fibroblasts have been shown to express CRH
as well as the CRF1 receptor [22]. To assess the relevance of our
findings in human cells, we isolated fibroblasts from juvenile
human foreskin and cultured them in the presence of the CRF1
specific antagonist anatalarmin or vehicle. Exposure of human
foreskin fibroblasts to antalarmin (100 nM) resulted in an increase
of their proliferation (Fig. 5a) and migration rate (Fig. 5b) while it
suppressed IL-6 production (Fig. 5c). In contrast, treatment of the
cells with Astressin 2B (a specific CRF2 antagonist) had no effect
on either their proliferation or migration rates. The findings in
human fibroblasts are similar with the above described mouse data
suggesting that a significant degree of similarity exists in the
CRH in Mouse and Human Fibroblasts
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primary fibroblasts function.
Effects of neutralization of IL-6 and TGF-b1 on the
proliferation and migration rate of dermal fibroblasts
To determine the impact of the lower IL-6and TGF-b1 secretion
on the higher proliferation and migration rate of Crh/2/2
fibroblasts we immunoneutralized either of the factors using specific
antibodies in cultures of Crh+/+ mouse and human fibroblasts. We
found that blockade of either IL-6 or TGF-b1 did not alter either
the migration or the proliferation rate of both mouse and human
fibroblasts (data not shown).
Discussion
The present study examines the role of endogenous CRH (i.e.
CRH produced within the skin) on the biology of dermal
fibroblasts. For this purpose we have used fibroblasts isolated
from the skin of wildtype (Crh+/+) and Crh deficient (Crh2/2)
mice as well as from normal human foreskin. To our knowledge,
this is the first report on the expression of the CRH gene in murine
fibroblasts and on its role in several key functions of these cells.
Our data suggest that locally produced CRH plays an important
role in the biology of murine and human skin fibroblast, an effect
inferred from our observations in Crh+/+ and Crh2/2 mice as
well as from normal human foreskin.
More specifically, we first demonstrate that murine fibroblasts
isolated from neonatal skin express CRF, in contrast to the
reported lack of expression in fibroblasts isolated from the skin of
adult or adolescent mice [22] [30]. This discrepancy in the
expression could be attributed to the different source of fibroblasts,
or age, or developmental stage. We also found that both types of
CRH receptors, CRF1 and CRF2 are expressed in dermal
fibroblasts and that they are fully functional since they are able
to bind the ligand in a specific manner and that their activation
results in cAMP production (Fig. 1). These data are in agreement
Figure 1. Mouse dermal fibroblasts express Crh and its receptors. (a) Total RNA isolated from whole brain from Crh+/+ mice (lane 1), NMF
isolated from Crh+/+ mice (lane 2) and NMF isolated from Crh2/2 mice (lane 3) was subjected to RT-PCR for evaluation of Crh expression. Lane 4
represents a sample without RT-enzyme and lane 5 represents a sample without template. (b) Crf1 mRNA expression in NMF isolated from Crh+/+
mice (lane 2). Lane 1 represents Crf1 mRNA expression isolated from whole brain, while lane 3 represents a sample without RT-enzyme and lane 4 a
sample without template. (c) Crf2 mRNA expression in NMF isolated from Crh+/+ mice (lane 2). Lane 1 represents Crf1 mRNA expression isolated from
heart, while lane 3 represents a sample without RT-enzyme and lane 4 a sample without template. (d) Effects of antalarmin and astressin-2B on
specific [
125I] Tyr0-sauvagine binding to CRF1 and CRF2. Membrane homogenates from Crh+/+ and Crh2/2 fibroblasts were assayed for specific
binding with [
125I] Tyr0-sauvagine, as described in Materials and Methods. The bars represent the % decrease of specific binding. The mean 6 SEM
values are from 3 independent experiments, each performed with duplicate determinations. (e) Effect of CRH on cAMP accumulation in Crh+/+ and
Crh2/2 fibroblasts. Stimulation of cAMP accumulation by CRH was performed as described in Materials and Methods in intact cells. The mean 6 SEM
values are from 3 independent experiments, each performed with duplicate determinations. * represents statistical difference (P,0.05) between
genotypes exposed to the same treatment and # represents statistical difference (P,0.05) between different treatments in the same genotype.
doi:10.1371/journal.pone.0021654.g001
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express CRF1 receptor and its activity is regulated by exogenously
added CRF via activation of cAMP and IP3 [31] [32]. It should be
noted here that cAMP accumulation experiments were carried out
in intact cells which most likely retain their ability to produce
CRH. Thus, it seems that the endogenous CRH produced and
secreted from wildtype fibroblasts saturated the CRF1 and CRF2,
expressed in these cells, and maximally stimulated the CRF
receptor-mediated cAMP accumulation. To further confirm this
hypothesis we treated wildtype fibroblasts with specific antagonists
for CRF1 and CRF2 (antalarmin and astressin 2B, respectively),
that resulted in decreased cAMP accumulation in either case (data
not shown). This hypothetical model might explain the lack of an
additional effect of exogenously added CRH on cAMP accumu-
lation in Crh+/+ fibroblasts.
Subsequently, we describe accelerated basal proliferation as well
as migration rate in primary Crh2/2 compared to Crh+/+
fibroblasts with a simultaneous compromised IL-6 and TGF-b1
secretion. These findings suggest specific effects of endogenous
CRH at several independent indices of fibroblast biology both
under basal conditions as well as after the induction of in vitro
wounding. Previously published elegant studies have shown that,
although the CRH/CRF receptors system is expressed in both
human and mouse skin and it appears that it plays an important
role in cutaneous biology of both, there are species-specific
differences including the predominant receptor type expressed
[22]. To our surprise, pharmacological blockade of CRH in
primary human dermal fibroblasts induced a phenotype very
similar to what we have found in the Crh2/2 fibroblast.
In previous studies, we found paradoxically altered IL-6 levels in
Crh2/2 mice following turpentine-induced abscess formation,
although to the opposite direction of the one found in the
fibroblasts [21]. Tissue-specific effects related to the receptor
subtype expression, the predominant signaling pathway operating
as well as additional factors expressed in dermal fibroblasts may
provide an explanation for the above findings. The interaction
between IL-6 and TGF-b in dermal fibroblasts has not been
completely clarified. In other tissues, such as the lung, downreg-
ulation of IL-6 resulted in abrogation of TGF-b1–induced
fibroblast proliferation [33], while TGF-b1 itself increased
endogenous IL-6 levels [34]. Similarly, TGF-b1 expression was
induced in Il62/2 fibroblasts treated with recombinant IL-6 [35].
In conclusion,ourexperimentaldata obtained from Crh2/2 and
wildtype mice as well as from human foreskin fibroblast suggest that
the endogenously produced CRH plays an important physiological
role in several parameters of skin fibroblast function. In essence, the
primary effect of endogenous CRH appears to be suppressive and
pro-inflammatory. Our current data add on previous reports on the
physiological significance of stress neuropeptides on the function of
skin fibroblasts and wound healing. Furthermore, our results may
have significant implications in the design of new therapeutic
antagonists targeting dermal fibroblasts in wound healing.
Materials and Methods
Ethics statement
All animal experiments were approved by the Animal
Committee of the Medical School of the University of Crete and
the Veterinary Department of Heraklion Prefecture. The Animal
Figure 2. Proliferative response of Crh+/+ and Crh2/2 fibroblasts. (a) Fibroblasts isolated from Crh+/+ and Crh2/2 dermis plated at an initial
density of 8610
3 cells/well for four days. * represents statistical difference (P,0.05) between genotypes. (n=4 wells/treatment/experiment, at least 5
independent experiments). (b) Fibroblasts isolated from both genotypes cultured at an initial density of 10
5 cells/well in serum supplemented or
serum free medium for 30 hr and apoptosis was measured by staining cells with Annexin V/Propidium Iodide and flow cytometry. The experiment
was performed three times, with representative results of one experiment shown here.
doi:10.1371/journal.pone.0021654.g002
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licensed by the Veterinary Department of Heraklion Prefecture.
All experiments with human fibroblasts cultures were approved by
the Ethics Committee of the University Hospital of Heraklion
(Official name of the Committee). A written consent was obtained
from all participants involved in the study.
Isolation and culture of murine and human dermal
fibroblasts
Primary murine dermal fibroblasts were isolated from the skin
of Crh+/+ and Crh2/2 neonatal mice, of 129xC57BL/6 genetic
background, (derived from Crh+/+6Crh+/+ and Crh2/26Crh2/
2 matings, respectively), as previously described with some
modifications [2]. Briefly, newborn Crh+/+ and Crh2/2 mice
(0–48 hours old) were sacrificed by decapitation, treated for
10 min in a povidine–iodine bath, followed by a 10 min 70%
ethanol bath and the whole skin was removed. Excised mouse skin
was placed in Petri dishes with the dermis side down, in Dulbecco-
PBS buffer (Invitrogen, Grand Island, N.Y., USA) containing
10 mg/ml dispase II (Sigma, Germany) and incubated at 4uC,
overnight. Isolated dermal tissue was then cut and placed in tissue
culture plates. Fibroblasts were cultured in DMEM (Gibco-BRL,
Gaithersburg, MD) with 10% fetal bovine serum (Gibco-BRL) and
1% penicillin/streptomycin (Gibco-BRL) after the tissue had been
attached to the plate. The fibroblasts were checked for their
spindle shaped morphology and identified by immunostaining
with an anti-vimentin goat anti-mouse antibody (a kind gift by
Professor Christos Stournaras [36]) or anti-pancytokeratin mono-
clonal mixture antibody (Sigma) for keratinocyte contamination
(data not shown). The cells were then re-plated twice to deplete the
culture from residual keratinocytes that do not survive re-plating in
10% FBS-DMEM [37]. In all experiments, Crh+/+ and Crh2/2
cells at identical passage numbers (,5) were used. Human
fibroblast cultures were established, using the same protocol, from
explants of foreskin obtained at the time of circumcision for
unrelated problems.
Fibroblast proliferation rates
The proliferation rate of murine and human fibroblasts was
determined with the MTT and the thymidine incorporation
methods [38]. For both methods, fibroblasts from either species
were cultured at an initial concentration of 8,000 cells/well, in flat-
Figure 3. Enhanced migratory response of Crh2/2 fibroblasts. Fibroblasts isolated from Crh+/+ and Crh2/2 dermis were allowed to attach
on the dish. A clear space was produced in the confluent monolayer, cultured in serum free or serum treated with 10 mg/ml mytomycin and the
wounded fibroblast layer was photographed immediately and 24 and 48 h after wounding. The distance of migration from the original borders was
determined and is indicated (b) as a percentage of the original distance in a representative experiment. * represents statistical difference (P,0.05)
between genotypes. (n=3 wells/treatment/experiment, at least 4 independent experiments).
doi:10.1371/journal.pone.0021654.g003
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supplemented medium. The cells were left to rest overnight and
then exposed to the tested substances or their vehicles in serum
and serum free conditions, as described in the Results. For the
MTT method, at the end of the incubation period, MTT (Sigma)
was added to each well at a final concentration of 0.5 mg/ml and
cells were incubated for an additional 4 h at 37uC. Crystals were
dissolved using DMSO (Sigma), and the optical density was read
on a Microplate Reader, Biorad. For the thymidine incorporation
method, at the end of the incubation period, [
3H] Thymidine
(Amersham Biosciences, Munich, Germany) was added to each
well at a final concentration 1 mCi/well, and cells were incubated
for an additional 24 h. Cells from each well were harvested onto
glass-fiber filters (Whatman, England) using a semi-automatic
harvester (Skatron Instruments AS, Lier, Norway). The incorpo-
rated radioactivity was counted using a b-counter (Perkin Elmer,
Foster City, CA).
Fibroblast apoptosis rates
Murine Crh+/+ and Crh2/2 fibroblasts were cultured in 6-well
plates. Twenty four hours later the medium was aspirated and
replaced either with serum supplemented or serum free medium.
Apoptosis was quantified at several time points with annexin V-
FITC and Propidium Iodide (BD Pharmingen, Franklin Lakes,
NJ, USA) by following manufacturer’s instructions. Briefly,
detached by trypsin, cells were washed twice with cold PBS and
then harvested in Binding Buffer (provided in the kit). Annexin V-
FITC (4 ml) and PI (3 ml) was added in 100 ml/10
5 cells and
incubated for 15 min at RT in the dark. At the end of the
incubation period, 400 ml of BB was added and the cells were
analyzed at a Beckton-Dickinson FACSArray apparatus (BD
Pharmigen) using the CELLQuest software.
Isolation of total RNA and Semi quantitative RT-PCR
Total RNA preparation and RT-PCR was performed as we have
previously described [39]. The primers for the mouse specific mRNAs
were obtained from VBC Biotech (Vienna, Austria). The sequence of
the primers used and the expected size of the corresponding products
are listed below:
Primers Size of product (bp)
Mouse
b-actin sense: 59-TCAGAAGGACTCCTATGTGG-39 500
b-actin antisense: 59-TCTCTTTGATGTCACGCACG-39
CRF1 sense: 59-GCCGCCTACAATTACTTCCA-39 310
CRF1 antisense: 59-CGGAGTTTGGTCATGAGGAT-39
CRF2 sense: 59-CTGGTGGCTGCTTTCCTGCTT-
TTC-39 407
CRF2 antisense: 59-ATGGGGGCCCTGGTAGATGT
AGTCC-39
CRH sense: 59-AGCCCTTGAATTTCTTGCA-39 202
CRH antisense: 59-AACACGCGGAAAAAGTTA-39
Amplification of the cDNA was done using the conditions: 96uC
for 3 min for denaturation, following by 40 cycles (25 cycles for b-
actin) for 1 min at 94uC, annealing at 55–65 depending on the
primers uC for 1 min, and extension at 72uC for 2 min. Reactions
were completed after an additional 5-min extension at 72uC. The
amplification reactions for all PCRs performed were analyzed on
1.3% agarose gels.
IL-6 and TGF-b1
Murine and human fibroblasts were cultured at an initial
concentration of 75,000 cells/well, in 24-well plates. The day of
the experiment the media were replaced with fresh serum-free
media containing vehicle or the tested substances, as indicated in
the figure legends. Culture media were collected at the indicated,
in the Results, time points and stored at 280uC until used. Human
IL-6 levels were measured by chemiluminescence on Immulite
1000 [40]. Murine IL-6 and TGF-b1 levels were evaluated using
commercial ELISA kits according to the instructions of the
manufacturer (R&D Systems, Minneapolis, MN, USA). For the
IL-6 and TGF-b1 immunoneutralization studies, the antibodies
were purchased from R&D Systems and were used at concentra-
tions of 1 mg/ml. Cells from both species were collected for protein
extraction and measurement.
CRH Peptide Enzyme Immunoassay (EIA)
Peptide in culture media was concentrated by a C-18 reverse
phase column (Sep-Pak, Waters Associates, Milford, MA) after
acidification in 2 vol 0.1 N HCI and centrifuged at 1500 rpm for
10 min. The supernatants were extracted by activated Sep-Pak
cartridges, washed with 20 ml 0.1 N HCI eluted with 3 ml
acetonitrile 80%-0.01% HCI, then dried under vacuum (Speed-
Vac). The IR-CRH content of the Sep-Pak extracts was assayed
by an EIA kit according to the manufacturer’s instructions
(Peninsula Laboratories, USA). The average IC50 of the assay
was 0.5 ng/ml and the crossreactivity was 100% with mouse,
human, and rat CRF, and 0% for Urocortins. Results were
expressed as nanograms of IR-CRH per microgram of total
cellular protein determined on whole cellular homogenates by the
Bradford method.
Figure 4. IL-6 and TGF-b1 production from Crh+/+ and Crh2/2
fibroblasts. Primary dermal fibroblasts isolated from Crh+/+ and Crh2/2
mice were cultured in 24-well plates (10
5 cells/well). Supernatants were
collected and analyzed by ELISA for IL-6 (a) or TGF-b1 (b). * represents
statistical difference (P,0.05) between genotypes (n=3 wells/condition/
experiment, at least 3 independent experiments).
doi:10.1371/journal.pone.0021654.g004
CRH in Mouse and Human Fibroblasts
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Murine and human fibroblasts were cultured in 12-well plates
until they reached confluency. The day of the experiment the
media were replaced with fresh media containing vehicle or the
tested substances and the scratch (in vitro wound) was performed
as previously described [41] with a tip. Images were captured at
several time points (indicated in the figure legends) and cell
migration was quantified by measuring the distance with the
program Image J (http://rsbweb.nih.gov/ij/) between two certain
points on either side of the gap. For proper statistical evaluation, at
least three measurements at different points were performed at
each image.
Binding assays
Harvesting cells and membrane preparation. Fibroblasts
from Crh+/+ and Crh2/2 neonates were washed with PBS, at
room temperature, briefly treated with PBS containing 2 mM
EDTA (PBS/EDTA), and then dissociated in PBS/EDTA.
Membrane suspensions were prepared as described previously
[42].
125I-Tyr
0-sauvagine (PerkinElmer, Waltham, MA, USA)
binding studies were performed as previously described [42].
Aliquots of diluted membrane suspension (50 ml) were incubated
with 350–400 pM
125I-Tyr
0-sauvagine with or without 500 nM
Astressin-2B (a kind gift from Dr. Spiess), 1000 nM antalarmin (a
gift from Dr. G. Chrousos) in a final volume of 0.1 ml. The
mixtures were incubated at 20–21uC for 120 min and then filtered
through glass fiber filters (934AH; Whatman) presoaked for 1 h in
0.3% polyethylenimine at 4uC. The filters were washed 36with
0.5 ml of ice-cold PBS, pH 7.1, containing 0.01% Triton X-100
and assessed for radioactivity in a gamma counter (LKB Wallac
1275 minigamma, 80% efficiency).
cAMP accumulation assays
Fibroblasts from both genotypes were plated in 6-well cell culture
plates. When the cells became 95 to 100% confluent the medium was
removed, and 500 ml of assay buffer was added [42]. After 1 hr
incubation at37uC,morebufferwithout(basallevels)orwith250 nM
CRH, 1000 nM antalarmin, or 1000 nM astressin 2B was added to a
Figure 5. Effect of the CRH antagonists in human dermal fibroblasts. (a) HDFs isolated from human foreskin were cultured in 96-well plates
(8,000 cells/well) in the presence of 100 nM antalarmin or ethanol (control). Proliferation was measured using either MTT or thymidine incorporation.
*: represents statistical difference (P,0.05) between treatments (n=4 wells/treatment/experiment, at least 3 independent experiments). (b) HDFs
were allowed to attach on the 100 mm dish. A clear space was produced in the confluent monolayer, cultured in serum free or serum treated with
10 mg/ml mytomycin and the wounded fibroblast layer was photographed immediately and 24 h after wounding (n=3 wells/treatment/experiment,
at least 3 independent experiments). (c) HDFs were cultured in 24-well plates (10
5 cells/well) in the presence of 100 nM antalarmin or ethanol
(control). Supernatants were collected and analyzed by ELISA. * represents statistical difference (P,0.05) between treatments (n=3 wells/condition/
experiment, at least 3 independent experiments). (d) HDFs were cultured in 96-well plates (8,000 cells/well) in the presence of 1000 nM astressin 2B
or ethanol (control). Proliferation was measured with MTT, (n=4 wells/treatment/experiment, at least 3 independent experiments).
doi:10.1371/journal.pone.0021654.g005
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at 37uC. At the end of the incubation, the buffer was removed. The
cells were plated on ice and lysed with 1% trichloroacetic acid.
Lysates were incubated on ice for 45 min, sonicated for 4 sec and
stored at 280uC. Frozen lysates were thawed, centrifuged at 1700 g
for 10 min at 4uC, and the supernatants were neutralized with 2N
NaOH. Quantification of cAMP in the neutralized supernatants was
performed using a competitive binding assay as described previously
[42]. The amount of cAMP in each sample was determined by
comparison with a standard curve of known concentrations of
unlabeled cAMP.
Statistical analysis
All values are expressed as the Mean 6 SEM of data obtained
from at least three independent experiments. Data were analyzed
by Student’s t-test and one-way analysis of variance (ANOVA)
followed by post-hoc multiple comparison tests. Significance was
accepted at p,0.05.
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